Intellia Therapeutics Files 8-K

Ticker: NTLA · Form: 8-K · Filed: May 19, 2025 · CIK: 1652130

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: NTLA

TL;DR

Intellia filed an 8-K, check for updates.

AI Summary

Intellia Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting events as of May 18, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Intellia Therapeutics is providing updates to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial data that would indicate a high-risk situation.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Intellia Therapeutics, Inc.?

The filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating updates on company events.

On what date was this 8-K filing submitted to the SEC?

The filing was submitted on May 19, 2025.

What is the earliest event date reported in this filing?

The earliest event reported is May 18, 2025.

Where are Intellia Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.

What are the key items disclosed in this 8-K filing?

The filing includes information for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Intellia Therapeutics, Inc. (NTLA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing